Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / chronic weight management (plans that elected weight-loss coverage) | Covered with prior authorization |
| Cardiovascular risk reduction and MASH (Wegovy, plans without weight-loss coverage) | Covered with prior authorization |
| Obstructive sleep apnea (Zepbound, plans without weight-loss coverage) | Covered with prior authorization |
UnitedHealthcare's weight-loss coverage runs through an optional program. Its own 2026 policy document opens by calling it "an optional program that is put in place for clients or businesses that have elected to cover weight loss products." If your employer bought that benefit, Wegovy and Zepbound are covered with prior authorization at BMI 30, or BMI 27 with a weight-related comorbidity. If your employer did not buy it, weight loss is excluded and only three narrower pathways remain: Wegovy for cardiovascular risk, Wegovy for MASH, and Zepbound for sleep apnea.
Source: UnitedHealthcare Pharmacy Clinical Pharmacy Programs, Prior Authorization/Notification: Plans with Weight Loss/Appetite Suppression Medication Coverage, Program 2026 P 1114-21, effective July 1, 2026. Verified August 15, 2026.
Plan type: Commercial employer-sponsored plans (fully insured and self-funded).
What it costs once they say yes. With commercial insurance the manufacturer savings card takes Wegovy or Zepbound to as little as $25 a month. Your plan sets the copay before the card applies. What Wegovy costs with your plan. What Zepbound costs with your plan.
This varies by plan. The weight-loss prior-authorization program is optional and only applies to employers that elected to cover weight-loss products. The separate non-formulary policies for Wegovy and Zepbound both state that "medications for the purpose of weight loss are typically a benefit exclusion." Two people holding identical UnitedHealthcare cards can have opposite answers depending on who they work for. Read the prescription drug section of your summary plan description, or call the member services number on your card and ask specifically whether your plan covers weight-loss medications. OptumRx is the pharmacy benefit manager.
Coverage by indication
| BMI threshold | BMI 30 or higher (or above the 95th percentile for pediatric patients), or BMI 27 or higher with a weight-related comorbidity. The policy names dyslipidemia, hypertension, type 2 diabetes and sleep apnea as examples. |
| Step therapy | None. The 2026 criteria do not require a trial of phentermine, orlistat or any other weight-loss drug first. They require only that the medication be used as an adjunct to lifestyle modification, described as dietary or caloric restriction, exercise, behavioral support or a community-based program. No minimum duration for that lifestyle trial is stated. |
| Continuation | Weight loss of 5 percent or more of baseline body weight, plus continuation of lifestyle modification |
| Authorization length | Wegovy injection or tablet 5 months initial. Zepbound 6 months initial. 12 months for reauthorization of either. |
What the prior authorization needs:
- Your employer must have elected weight-loss drug coverage. Program 2026 P 1114-21 applies only to plans that did.
- Age 12 or older for Wegovy injection, and older than 16 for Zepbound
- Documented BMI within the accepted threshold
- Comorbidity documentation when BMI is 27 to 29.9
- Used as an adjunct to lifestyle modification
- Reauthorization requires 5 percent loss of baseline body weight
Policy 2026 P 1114-21. Source: UnitedHealthcare Pharmacy Clinical Pharmacy Programs, Prior Authorization/Notification: Plans with Weight Loss/Appetite Suppression Medication Coverage, Program 2026 P 1114-21, effective July 1, 2026. Official payer prior-authorization program document (PDF downloaded from uhcprovider.com and read in full). Verified August 15, 2026.
This is the pathway for members whose plan does not cover weight-loss drugs. The policy states that "medications for the purpose of weight loss are typically a benefit exclusion" and that the program allows coverage of Wegovy injection or tablet for cardiovascular risk reduction and Wegovy injection for MASH. A qualifying BMI is not enough on this pathway, because approval turns on documented cardiovascular disease or documented MASH.
| BMI threshold | BMI 27 or higher |
| Cardiovascular criteria | Established cardiovascular disease evidenced by prior myocardial infarction, prior ischemic or hemorrhagic stroke, or symptomatic peripheral arterial disease shown by intermittent claudication with a resting ankle-brachial index below 0.85, a peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease. |
| Step therapy | No weight-loss drug step therapy. Instead the patient must already be on guideline-directed cardiovascular therapy from each applicable class unless contraindicated or not tolerated: cholesterol-lowering medication for all three histories, plus a beta blocker for prior myocardial infarction, plus an ACE inhibitor, ARB or ARNI, plus an antiplatelet. |
What the prior authorization needs:
- Age 45 or older
- BMI 27 or higher
- Documented established cardiovascular disease
- Concurrent guideline-directed cardiovascular pharmacotherapy from each applicable class unless contraindicated or not tolerated
- Used with a reduced-calorie diet and increased physical activity
Policy 2026 P 1445-4. Source: UnitedHealthcare Pharmacy Clinical Pharmacy Programs, Prior Authorization/Non-Formulary: Wegovy (semaglutide) injection and tablets, Cardiovascular Risk Reduction and MASH Only, Program 2026 P 1445-4, effective May 1, 2026. Official payer non-formulary prior-authorization document (PDF downloaded from uhcprovider.com and read in full). Verified August 15, 2026.
This is the route for members whose plan excludes weight-loss drugs. The policy states that "medications for the purpose of weight loss are typically a benefit exclusion" and that the program allows coverage of Zepbound for obesity with obstructive sleep apnea.
| BMI threshold | BMI 30 or higher |
| Sleep study (AHI) | Moderate to severe obstructive sleep apnea on a sleep study, with an apnea-hypopnea index, respiratory event index or respiratory disturbance index above 15 events per hour |
| Step therapy | PAP therapy is effectively the step. The patient must either have continued OSA symptoms despite PAP adherence, defined as at least 4 hours of use per night on at least 70 percent of nights, or be documented as not a PAP candidate. |
| Continuation | Under 52 weeks of therapy: any documented decrease from baseline in AHI, RDI or REI. At 52 weeks or more: a 50 percent decrease from baseline. Either way, 10 percent loss of baseline body weight is also required. |
| Authorization length | 6 months initial. Reauthorization 6 months under 52 weeks of therapy, 12 months at 52 weeks or more. |
What the prior authorization needs:
- Age 18 or older
- BMI 30 or higher
- Sleep study documenting AHI, REI or RDI above 15 events per hour
- At least one previous unsuccessful dietary effort to lose weight
- Continued symptoms despite documented PAP adherence, or documentation that the patient is not a PAP candidate
- No diabetes diagnosis and A1c at or below 6.5 percent
- Prescriber attestation of counseling on positional therapy and on avoiding alcohol or sedatives before bed
- No planned surgery for sleep apnea or obesity, and no predominant central or mixed sleep apnea
- Prescribed by or in consultation with a sleep specialist
Policy 2025 P 1475-2. Source: UnitedHealthcare Pharmacy Clinical Pharmacy Programs, Prior Authorization/Non-Formulary: Zepbound (tirzepatide), Obstructive Sleep Apnea Only, Program 2025 P 1475-2, effective March 1, 2026. Official payer non-formulary prior-authorization document (PDF downloaded from uhcprovider.com and read in full). Verified August 15, 2026.
Recent change: UnitedHealthcare's weight-loss program document was reapproved by its P&T committee in November 2025, February 2026 and April 2026, and the current version took effect July 1, 2026. The 2026 criteria require only that the drug be used as an adjunct to lifestyle modification, with no minimum duration stated. Reauthorization requires 5 percent weight loss.
Ozempic, Mounjaro and Rybelsus on UnitedHealthcare plans
Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss.
Does UnitedHealthcare cover Ozempic?
Yes, with prior approval. UnitedHealthcare pays for Ozempic once your prescriber gets the plan to sign off.
UnitedHealthcare, through OptumRx, covers Ozempic for adults with type 2 diabetes on its 2026 commercial drug list, with prior authorization and a quantity limit. Approval requires records confirming a type 2 diabetes diagnosis, shown by an A1C of 6.5 percent or higher or another qualifying lab value, or chart notes for patients diagnosed more than two years ago. The 2026 policy does not require step therapy, and an approval lasts 12 months. UnitedHealthcare does not cover Ozempic for weight loss, which is off-label and excluded from most plans. That indication belongs to Wegovy, the same semaglutide at a higher dose.
Commercial non-Medicare. Verified August 27, 2026.
What UnitedHealthcare requires for Ozempic
What the prior authorization needs:
- Prior authorization required under UnitedHealthcare clinical program 2026 P 1332-8, effective July 1, 2026.
- Medical records confirming type 2 diabetes, evidenced by one of: A1C greater than or equal to 6.5 percent, fasting plasma glucose greater than or equal to 126 mg/dL, 2-hour plasma glucose greater than or equal to 200 mg/dL on an oral glucose tolerance test, or random plasma glucose greater than or equal to 200 mg/dL with classic symptoms of hyperglycemia.
- For patients diagnosed more than 2 years ago, chart notes confirming the type 2 diabetes diagnosis are accepted.
- Authorization is issued for 12 months.
- No step therapy required. The April 2025 revision removed the note that step therapy may apply.
- Quantity limit (QL) applies per the 2026 commercial Prescription Drug List (effective January 1, 2026), where Ozempic also carries the 'E' designation, meaning it may be excluded from coverage or subject to prior authorization in Connecticut, New Jersey and New York. PDL source: https://www.uhcprovider.com/content/dam/provider/docs/public/resources/pharmacy/commercial-pdl-jan-2026.pdf
- Not FDA-approved for weight loss. Medications used for weight loss are typically excluded from benefit coverage.
Policy 2026 P 1332-8. Source: UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Prior Authorization/Notification: Diabetes Medications, GLP-1 & Dual GIP/GLP-1 Receptor Agonists. Program Number 2026 P 1332-8. payer_policy. Verified August 27, 2026.
Recent change: UnitedHealthcare's April 2025 revision to this GLP-1 program removed the prior note that step therapy may apply, so the current 2026 program does not require a metformin trial before approving Ozempic for type 2 diabetes. The program was reaffirmed at annual review with an effective date of July 1, 2026.
Does UnitedHealthcare cover Mounjaro?
Yes, with prior approval. UnitedHealthcare pays for Mounjaro once your prescriber gets the plan to sign off.
UnitedHealthcare covers Mounjaro for type 2 diabetes on its commercial plans, with prior authorization handled through OptumRx. It will not cover Mounjaro for weight loss, because Mounjaro is FDA-approved only for type 2 diabetes. The weight-loss version of the same drug, tirzepatide, is Zepbound, which UnitedHealthcare handles under a separate policy. To approve Mounjaro, the plan asks for records confirming a type 2 diabetes diagnosis, and an approval runs for 12 months.
Commercial non-Medicare. Verified August 27, 2026.
What UnitedHealthcare requires for Mounjaro
What the prior authorization needs:
- Prior authorization is required, handled through OptumRx.
- Medical records confirming a type 2 diabetes diagnosis, shown by one lab value: A1C of 6.5% or higher, fasting plasma glucose of 126 mg/dL or higher, a 2-hour glucose of 200 mg/dL or higher on an oral glucose tolerance test, or a random glucose of 200 mg/dL or higher with symptoms.
- For patients diagnosed more than two years ago, medical records confirming the type 2 diabetes diagnosis are enough.
- No step therapy is required.
- Supply limits may apply.
- Approval is issued for 12 months.
Policy 2026 P 1332-8. Source: UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Prior Authorization/Notification: Diabetes Medications. GLP-1 & Dual GIP/GLP-1 Receptor Agonists. payer coverage policy. Verified August 27, 2026.
Recent change: UnitedHealthcare removed the step therapy requirement for Mounjaro in its April 2025 update, so patients no longer need to try and fail another diabetes drug first. The current policy, effective July 1, 2026, keeps that change.
Does UnitedHealthcare cover Rybelsus?
Yes, with prior approval. UnitedHealthcare pays for Rybelsus once your prescriber gets the plan to sign off.
UnitedHealthcare and OptumRx cover Rybelsus for type 2 diabetes under commercial plans, but it requires prior authorization. Approval needs medical records confirming a type 2 diabetes diagnosis, shown by an A1C of 6.5% or higher, a fasting plasma glucose of 126 mg/dL or higher, or another qualifying glucose value; patients diagnosed more than two years ago can qualify with records confirming the diagnosis. Rybelsus is not covered for weight loss, because it is FDA-approved only for type 2 diabetes and weight-loss drugs are typically excluded from the benefit. Wegovy is the weight-loss version of semaglutide.
Commercial non-Medicare. Verified August 27, 2026.
What UnitedHealthcare requires for Rybelsus
What the prior authorization needs:
- Prior authorization required.
- Medical records confirming a type 2 diabetes diagnosis, shown by one of: A1C 6.5% or higher, fasting plasma glucose 126 mg/dL or higher, 2-hour plasma glucose 200 mg/dL or higher during an oral glucose tolerance test, or random plasma glucose 200 mg/dL or higher with classic symptoms of hyperglycemia.
- For patients requiring ongoing treatment diagnosed more than 2 years ago, medical records confirming the type 2 diabetes diagnosis.
- No step therapy in the current program. The metformin trial requirement was removed in the April 2024 update.
- Authorization is issued for 12 months.
Policy 2026 P 1332-8. Source: Prior Authorization/Notification: Diabetes Medications, GLP-1 and Dual GIP/GLP-1 Receptor Agonists. payer_prior_authorization_policy. Verified August 27, 2026.
Recent change: Effective 7/1/2026 under program 2026 P 1332-8 (P&T approval 4/2026). The April 2024 revision removed step therapy from this program, so a metformin trial is no longer required. Some third-party summaries still list a metformin step, which the current policy does not.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does UnitedHealthcare cover Wegovy for weight loss?
Only if your employer elected the benefit. UnitedHealthcare's weight-loss prior-authorization program (2026 P 1114-21, effective July 1, 2026) is described in the policy itself as optional and put in place for clients that have elected to cover weight-loss products. On plans that elected it, Wegovy is approved at BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea, used as an adjunct to lifestyle modification. Initial authorization runs 5 months. Reauthorization runs 12 months and requires 5 percent loss of baseline body weight plus continued lifestyle modification. On plans that did not elect it, Wegovy is covered only for cardiovascular risk reduction or MASH under a separate non-formulary policy.
Does UnitedHealthcare cover Zepbound?
On plans that elected weight-loss coverage, yes, with prior authorization, under the same BMI thresholds as Wegovy. Initial authorization runs 6 months, reauthorization 12 months, and reauthorization requires 5 percent loss of baseline body weight. On plans that did not elect weight-loss coverage there is one remaining route: Zepbound for moderate to severe obstructive sleep apnea, under policy 2025 P 1475-2. That route is narrow. It requires BMI 30 or higher, a sleep study showing an apnea-hypopnea index above 15, no diabetes diagnosis and A1c at or below 6.5 percent, a prescription written by or in consultation with a sleep specialist, and either continued symptoms despite PAP adherence of at least 4 hours a night on 70 percent of nights, or documentation that you are not a PAP candidate.
What BMI does UnitedHealthcare require for GLP-1 coverage?
BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity. The 2026 policy names dyslipidemia, hypertension, type 2 diabetes and sleep apnea as examples rather than as a closed list. Pediatric patients qualify at a BMI above the 95th percentile. The sleep-apnea pathway for Zepbound on plans without weight-loss coverage uses a stricter threshold: BMI 30 or higher, with no BMI 27 option. The cardiovascular pathway for Wegovy uses BMI 27 or higher and additionally requires the patient to be 45 or older.
Why might UnitedHealthcare deny Wegovy even if I meet the BMI criteria?
The most common reason has nothing to do with your BMI. It is that your employer never bought the weight-loss benefit, which UnitedHealthcare's own non-formulary policies describe as the typical case. Beyond that: the reauthorization gate at 5 percent weight loss ends coverage for people who respond slowly; the cardiovascular pathway requires documented guideline-directed therapy from each relevant drug class (statin, beta blocker, ACE inhibitor or ARB, antiplatelet) unless contraindicated; and the sleep-apnea pathway requires a sleep specialist and documented PAP failure or non-candidacy. If the benefit was never elected, no amount of clinical documentation fixes it. The route is a formulary exception, an appeal on the benefit design, or a different plan at open enrollment.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
